Ali Tahmasebi, Nazanin Ebrahimiadib, Mohammadreza Niyousha, Narges Hassanpoor
{"title":"既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用法利昔单抗：一项系统回顾和荟萃分析","authors":"Ali Tahmasebi, Nazanin Ebrahimiadib, Mohammadreza Niyousha, Narges Hassanpoor","doi":"10.1007/s00417-025-06878-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess functional and anatomical results of switching to faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab and/or ranibizumab and/or aflibercept in persistent diabetic macular edema (DME).</p><p><strong>Methods: </strong>We performed a systematic search of literature across four primary electronic databases (PubMed, Embase, Web of Science, and Scopus) prior to January 2025 to find the articles on switching to faricimab in refractory DME. Therapeutic effect parameters, including mean change of best-corrected visual acuity (BCVA), central macular thickness (CMT) and injection intervals were extracted from baseline to different follow-up timelines.</p><p><strong>Results: </strong>Six hundred twenty-nine eyes from 564 patients of fifteen studies, published between 2022 and January 2025, were included in this systematic review, all of which employed a retrospective cohort design. Most participants in the included studies had prior anti-VEGF therapies which were predominantly aflibercept, with fewer cases received ranibizumab and/or bevacizumab. Meta-analysis showed that BCVA improved significantly () in both 1 month and 3 to 12 months after switching. The pooled mean difference was - 0.03 (95%CI: -0.06 to -0.01, ) at 1 month post faricimab injection and - 0.05 (95% CI: -0.08 to -0.03, ) at 3-12 months. CMT also showed significant improvement after switching to faricimab in different follow up periods including even one month and 3-12 months after first faricimab injection. The pooled mean difference was - 54.69 and - 103.5 μm, respectively. Moreover, the pooled results from six studies indicate a significant prolongation in treatment intervals, with a mean difference of 1.53 weeks.</p><p><strong>Conclusion: </strong>Based on this meta-analysis, switching to faricimab can be considered for patients with persistent DME and can lead to functional or anatomical improvement.</p>","PeriodicalId":520634,"journal":{"name":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.\",\"authors\":\"Ali Tahmasebi, Nazanin Ebrahimiadib, Mohammadreza Niyousha, Narges Hassanpoor\",\"doi\":\"10.1007/s00417-025-06878-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To assess functional and anatomical results of switching to faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab and/or ranibizumab and/or aflibercept in persistent diabetic macular edema (DME).</p><p><strong>Methods: </strong>We performed a systematic search of literature across four primary electronic databases (PubMed, Embase, Web of Science, and Scopus) prior to January 2025 to find the articles on switching to faricimab in refractory DME. Therapeutic effect parameters, including mean change of best-corrected visual acuity (BCVA), central macular thickness (CMT) and injection intervals were extracted from baseline to different follow-up timelines.</p><p><strong>Results: </strong>Six hundred twenty-nine eyes from 564 patients of fifteen studies, published between 2022 and January 2025, were included in this systematic review, all of which employed a retrospective cohort design. Most participants in the included studies had prior anti-VEGF therapies which were predominantly aflibercept, with fewer cases received ranibizumab and/or bevacizumab. Meta-analysis showed that BCVA improved significantly () in both 1 month and 3 to 12 months after switching. The pooled mean difference was - 0.03 (95%CI: -0.06 to -0.01, ) at 1 month post faricimab injection and - 0.05 (95% CI: -0.08 to -0.03, ) at 3-12 months. CMT also showed significant improvement after switching to faricimab in different follow up periods including even one month and 3-12 months after first faricimab injection. The pooled mean difference was - 54.69 and - 103.5 μm, respectively. Moreover, the pooled results from six studies indicate a significant prolongation in treatment intervals, with a mean difference of 1.53 weeks.</p><p><strong>Conclusion: </strong>Based on this meta-analysis, switching to faricimab can be considered for patients with persistent DME and can lead to functional or anatomical improvement.</p>\",\"PeriodicalId\":520634,\"journal\":{\"name\":\"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00417-025-06878-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00417-025-06878-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Switching to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular edema: a systematic review and meta-analysis.
Purpose: To assess functional and anatomical results of switching to faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy with bevacizumab and/or ranibizumab and/or aflibercept in persistent diabetic macular edema (DME).
Methods: We performed a systematic search of literature across four primary electronic databases (PubMed, Embase, Web of Science, and Scopus) prior to January 2025 to find the articles on switching to faricimab in refractory DME. Therapeutic effect parameters, including mean change of best-corrected visual acuity (BCVA), central macular thickness (CMT) and injection intervals were extracted from baseline to different follow-up timelines.
Results: Six hundred twenty-nine eyes from 564 patients of fifteen studies, published between 2022 and January 2025, were included in this systematic review, all of which employed a retrospective cohort design. Most participants in the included studies had prior anti-VEGF therapies which were predominantly aflibercept, with fewer cases received ranibizumab and/or bevacizumab. Meta-analysis showed that BCVA improved significantly () in both 1 month and 3 to 12 months after switching. The pooled mean difference was - 0.03 (95%CI: -0.06 to -0.01, ) at 1 month post faricimab injection and - 0.05 (95% CI: -0.08 to -0.03, ) at 3-12 months. CMT also showed significant improvement after switching to faricimab in different follow up periods including even one month and 3-12 months after first faricimab injection. The pooled mean difference was - 54.69 and - 103.5 μm, respectively. Moreover, the pooled results from six studies indicate a significant prolongation in treatment intervals, with a mean difference of 1.53 weeks.
Conclusion: Based on this meta-analysis, switching to faricimab can be considered for patients with persistent DME and can lead to functional or anatomical improvement.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
